Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Partner operating in the Health Care space. If you think a Partner is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Matthew Howard
Managing Partner of Norwest Venture Partners
Follow Matthew Howard:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Promod Haque
Senior Managing Partner of Norwest Venture Partners
Promod has 31 years of experience in the venture capital industry and currently serves as senior managing partner at Norwest Venture Partners. Promod joined Norwest in 1990, and has invested in more than 70 companies since he began his venture career. His investments have been worth more than $40B in aggregate exit value to date, as 25 of his portfolio companies have gone public and 37 have been acquired (or have gone public and been acquired). In 2014 and 2016, Forbes recognized Promod as a “Hall of Fame” investor. 2017 marked Promod’s thirteenth appearance on the annual Forbes Midas List, including 2004, when he was ranked the #1 venture capitalist based on performance over the previous decade. In 2006, Promod was presented with a Global Leadership award from NASSCOM, and he was honored with the 2011 SV Forum Visionary Award based on his outstanding achievements and contributions to the technology industry.
Follow Promod Haque:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Edward Yip
Partner of Norwest Venture Partners
Follow Edward Yip:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Tiba Aynechi
General Partner of Norwest Venture Partners
Tiba Aynechi is a General Partner at Norwest. Prior to joining Norwest, Tiba spent over ten years at Novo Holdings A/S, one of the top life sciences investment firms, with offices in the US and Europe. Tiba attended the University of California Irvine where she received a Bachelor of Science degree in Physics with a Biomedical concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship.
Follow Tiba Aynechi:
About Norwest Venture Partners, Novo Ventures: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Dave Zilberman
General Partner of Norwest Venture Partners
Dave joined Comcast Ventures in 2006, and is responsible for identifying, executing and managing new investments while supporting existing portfolio companies. His investment focus is on enterprise IT and digital media. Prior to joining Comcast Ventures, Dave was a business development manager at Flarion Technologies, where he played a pivotal role in the company’s fundraising activities and ultimate acquisition by Qualcomm. Prior to Flarion, Dave was a communications and media investment banking analyst and asset management associate at Lehman Brothers. Dave holds a B.S. in Management with a concentration in Finance from Binghamton University.
Follow Dave Zilberman:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Sean Jacobsohn
Partner of Norwest Venture Partners
Follow Sean Jacobsohn:
About Creative Destruction Lab (CDL), Harvard Business School Alumni Angels of Greater NY, Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Lisa Wu
Partner of Norwest Venture Partners
Lisa focuses on early to late stage venture investments across a wide range of sectors at NVP, with an emphasis on consumer Internet. Before joining the NVP team, Lisa worked as an intern in Amazon.com’s Worldwide Corporate Development team. In this role, she identified and evaluated acquisition targets and strategic investments for Amazon and provided strategies for potential expansion. Prior to Amazon, Lisa worked at Bessemer Venture Partners, where she originated and conducted due diligence on early to growth stage investment opportunities, including several top eCommerce, SaaS, consumer Internet, and healthcare IT companies. Lisa has also worked in the venture capital arm of Comcast Corporation, and earlier, Lisa founded BANZAI! Fresh, a small business providing high-quality, nutritious foods to schools and hospitals in Northern California. Lisa began her career in the investment banking group at Merrill Lynch. Lisa holds an MBA from the Wharton School of the University of Pennsylvania with a double major in marketing and entrepreneurial management. While at Wharton, Lisa won first place at the International Venture Capital Investment Competition. Lisa also holds a bachelor of science, with honors, in business administration from the Haas School of Business at the University of California, Berkeley, and a bachelor of arts in psychology from the University of California, Berkeley.
Follow Lisa Wu:
About Calm, Jet, Norwest Venture Partners, Opendoor, Plaid: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Jon Kossow
Managing Partner of Norwest Venture Partners
Follow Jon Kossow:
About Clarus Commerce, Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
David Su
Partner of Norwest Venture Partners
Follow David Su:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Rama Sekhar
Partner of Norwest Venture Partners
Follow Rama Sekhar:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Sonya Brown
General Partner of Norwest Venture Partners
Follow Sonya Brown:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Priti Youssef Choksi
Partner of Norwest Venture Partners
Priti brings more than twenty years of corporate and business development experience to her role as a partner on Norwest’s consumer Internet team. Prior to Norwest, Priti spent nine years at Facebook in executive roles in corporate development and business development, where she led M&A efforts for the company, negotiated key partnerships, and served as a strategic advisor to product leadership teams across Facebook. Before her time at Facebook, Priti spent six years at Google in strategic partnership roles. As director of distribution partnerships, she led deals for Google applications such as Toolbar and Chrome and negotiated transformative search partnerships with companies such as Apple and Mozilla. Top-line revenue from these deals grew from $0 to $4 billion under her stewardship.
Follow Priti Youssef Choksi:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Casper De Clercq
General Partner of Norwest Venture Partners
Follow Casper De Clercq:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Jeff Crowe
Managing Partner of Norwest Venture Partners
Follow Jeff Crowe:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Parker Barrile
Partner of Norwest Venture Partners
Follow Parker Barrile:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Scott Beechuk
Partner of Norwest Venture Partners
Follow Scott Beechuk:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Robert Abbott
Partner of Norwest Venture Partners
Follow Robert Abbott:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Ryan Harris
General Partner of Norwest Venture Partners
Ryan brings to NVP more than twenty years of healthcare experience, a decade of which was as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in NVP’s Palo Alto office. Areas in which he invests include healthcare services, healthcare IT, medical devices, and specialty pharma. Ryan’s most recent investment is Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems. Prior to joining NVP, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare service, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture. At Carlyle, Ryan’s deals led to realized profitable exits of more than $1.8 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (NASDAQ: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps. At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies. Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics. Ryan holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
Follow Ryan Harris:
About Norwest Venture Partners, RiverMend Health: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Kurt Betcher
Administrative Partner of Norwest Venture Partners
Follow Kurt Betcher:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Matthew De Dominicis
Partner & Chief Financial Officer of Norwest Venture Partners
Matt has more than 16 years of experience in financial management. As Norwest’s Chief Financial Officer, he oversees the firm’s financial operations. Before joining Norwest, Matt was the Chief Financial Officer at Watershed Asset Management, an SEC-registered investment adviser. At Watershed, Matt was responsible for the diverse business operations of the firm, managing over $1 billion across multiple hedge funds. Prior to that, he was fund controller at Highland Capital Partners, where he was part of a team responsible for the finance function for multiple venture capital and private equity funds. Matt previously held positions at Sowood Capital Management, Liberty Mutual Group, and Ernst & Young. Matt holds a BBA with a major in accounting from the Mendoza College of Business Administration at the University of Notre Dame, and an MBA from the University of Massachusetts, Boston. Matt is a certified public accountant.
Follow Matthew De Dominicis:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Katie Belding
Partner, Portfolio Services of Norwest Venture Partners
Follow Katie Belding:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Scott Sandell
Managing General Partner of New Enterprise Associates
Scott Sandell is Managing General Partner at NEA. A General Partner since 2000, and Co-Managing General Partner from 2015 – 2017, Scott served as head of the firm’s technology investing practice for 10 years and has led NEA’s China investing activities for over a decade. Since joining the firm in 1996, he has personally led investments in industry-transforming companies like Bloom Energy, Data Domain, Fusion-io, Salesforce.com, Tableau Software, WebEx, and Workday. Scott is one of only four investors named to the Forbes Midas List every year since 2007, with 24 technology companies in his portfolio having successfully completed public offerings or mergers. Scott is currently a director of Bloom Energy (NYSE: BE) and a number of private companies including Automation Anywhere, Branch, Cloudflare, Coursera, Enigma, Expanse (fka Qadium), Hello Alfred, One Concern, Robinhood, Sentons, Transfix, and WaterBit. Other previous investments include Fusion-io (acquired by SanDisk), Neoteris (acquired by Juniper Networks), NetIQ (acquired by Attachmate Corporation), Playdom (acquired by Disney), and Spreadtrum Communications (acquired by Tsinghua Unigroup).
Follow Scott Sandell:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Greg Papadopoulos
Venture Partner of New Enterprise Associates
Follow Greg Papadopoulos:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Aaron Jacobson
Partner of New Enterprise Associates
Aaron Jacobson joined NEA in 2011 and is a Partner focused on investing in entrepreneurs seeking to build, scale and secure the next-generation of SaaS applications, big data platforms, and cloud infrastructure. He serves on the board of Tigera and illusive networks, and is an observer at NGINX, Streamsets, Move Guides, Mimosa Networks, Juvo, and Built Robotics. He has also worked closely with many other NEA portfolio companies including Box (NYSE:Box), Databricks, MapR, UnifyID, Bloom Energy, and Coursera. In 2016 he was named to Forbes Magazine’s “30 under 30” in Venture Capital and the Silicon Valley Business Journal’s “40 Under 40”. Prior to joining NEA, Aaron spent two years at Qatalyst Partners in San Francisco. At Qatalyst, Aaron worked as an Analyst engaged in various M&A transactions, which included the sale of PopCap Games to Electronic Arts, the sale of Riot Games to Tencent, the strategic investment in Go Daddy from KKR / Silver Lake / TCV, the sale of Palm to HP, and Conexant’s sale to Golden Gate Capital, among others. Aaron graduated Summa Cum Laude from the Jerome Fisher Program in Management and Technology at the University of Pennsylvania, where he earned dual Bachelor of Science degrees in Economics and Electrical Engineering, and carried a minor in Math.
Follow Aaron Jacobson:
About Illusive, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Vanessa Larco
Partner of New Enterprise Associates
Vanessa Larco joined NEA as a Partner in 2016 and focuses on Enterprise SaaS and Consumer Services investing. She is passionate about technology, services and products that enable people to be more productive and efficient at work and at home. Vanessa has led investments in Cleo, EvidentID, Greenlight Card, Feather, Lily AI and Mejuri. She is also a board observer at Robinhood and OmniSci. Prior to joining NEA, she was the Director of Product Management at Box (NYSE: BOX) where she worked on building the next generation of productivity apps across web and mobile. Her passion for design and analytics stems from her experience in the gaming industry, which includes leading the Speech Recognition Experience team at Xbox Kinect v1, and building a top grossing gaming studio at Disney Social. Vanessa holds a BS in Computer Science from the Georgia Institute of Technology.
Follow Vanessa Larco:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Jonathan Golden
Partner of New Enterprise Associates
Partner @NEA. Previously Product @Airbnb and @Dropbox
Follow Jonathan Golden:
About New Enterprise Associates, StartX (Stanford-StartX Fund): New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Ali Behbahani
General Partner of New Enterprise Associates
Ali Behbahani joined NEA’s healthcare team in 2007 and specializes in healthcare investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.
Follow Ali Behbahani:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Ben Narasin
Venture Partner of New Enterprise Associates
Ben Narasin is a Venture Partner at NEA. A prolific entrepreneur and highly regarded early-stage investor with three decades of company-building expertise, Narasin has focused on emerging technologies and new markets throughout his investment career. With a portfolio comprising key early successes in some of today’s fastest growing sectors, such as fintech, digital marketplaces, mobile and connected devices. His overarching focus in seeking new investments is, in his words, “to find founders who make me say wow.” Narasin is a 25-year entrepreneur and 10-year early-stage investor. His knack for spotting emerging trends led him to make seed investments in companies like Dropcam, Lending Club, TellApart, Kabbage and Zenefits. Before NEA, Narasin most recently served as a General Partner at Canvas Ventures, and was previously with TriplePoint Capital, where he oversaw the firm’s seed funding investment activities. Like many of NEA’s partners, Narasin’s path to investing is rooted in entrepreneurship. He founded several consumer companies before launching his investing career, including Fashionmall.com, one of the first e-commerce companies, which he founded in 1993 and led to a successful IPO in 1999. Narasin frequently writes and speaks about technology and investing, as well as food and wine, a lifelong passion. He holds a B.A. in Entrepreneurial Studies from Babson College
Follow Ben Narasin:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Paul Walker
General Partner of New Enterprise Associates
Paul Walker joined NEA in 2008. He focuses on later-stage biotechnology and life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation. He is a board member of TESARO and a board observer of Sunesis and manages a number of NEA’s other late-stage and public investments.
Follow Paul Walker:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Forest Baskett
General Partner of New Enterprise Associates
Forest joined NEA in 1999 as a Venture Partner and became a General Partner in 2004. Forest focuses on information and energy technology investments. He is the NEA representative on the boards of AstroWatt, Audience, Chelsio Communications, Serious Energy and SuVolta. He also assists Alta Devices, Azuray Technologies, Bandgap Engineering, Conviva, Firefly Green Technologies, Fusion-io (NYSE: FIO), Illumitex, Luxtera, NovaTorque, Solar Junction, Svaya Nanotechnologies, Tableau Software, Terrajoule and Tintri as either a board member, observer or advisor, usually in conjunction with another member of the NEA investing staff. In the past he has worked with, among others, Aeluros, Arch Rock, Atheros Communications, Data Domain, E2O, Fulcrum Microsystems, Nanochip, Newisys, RingCube Technologies, SiBEAM, Telegent Systems, and T-RAM Semiconductor. Forest also previously held advisory positions with FineGround, PolyServe, ReShape and SMIC. Prior to NEA, Forest was Senior Vice President of R&D and Chief Technology Officer of Silicon Graphics Inc. He founded and directed the Western Research Laboratory of Digital Equipment Corporation before joining SGI. Prior to that, he was a Professor of Computer Science and Electrical Engineering at Stanford University. Forest Baskett received a BA in Mathematics from Rice University, a Ph.D. in Computer Science from the University of Texas at Austin and is a member of the National Academy of Engineering.
Follow Forest Baskett:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Josh Makower
Special Partner of New Enterprise Associates
Josh joined NEA in September 2004 as a Venture Partner but has worked closely with NEA since his time as an NEA EIR back in 1995. He is currently a General Partner on NEA’s healthcare team and focuses primarily on medical devices and consumer health technologies. Josh is also the Founder & Chief Executive Officer of ExploraMed I, II, III, and IV Inc., a series of NEA portfolio medical device incubators based on the West Coast that have created eight companies over the past 20 years. Acclarent, Inc, an ExploraMed II company, was acquired by Johnson & Johnson in 2009. EndoMatrix, Inc. was acquired by C.R. Bard in 1997 and TransVascular, Inc. was acquired by Medtronic in 2003 (both companies were created by ExploraMed I). On-going ExploraMed/NEA ventures include NeoTract, Inc. (created by ExploraMed II), Moximed, Inc. (created by ExploraMed III) and Nuelle, Inc and NC7 (both created by ExploraMed IV). In addition, Josh serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh serves on the board of directors for ExploraMed II, III and IV, Intrinsic Therapeutics, Inc., NeoTract, Inc., Moximed, Inc., Ceterix, Inc., Nuelle, Inc, NC7 Inc. and Coravin. Prior to NEA, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group. Josh holds over one hundred patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, a medical degree from the New York University School of Medicine, and a bachelor’s degree in Mechanical Engineering from the Massachusetts Institute of Technology.
Follow Josh Makower:
About Coravin, DOTS, ExploraMed, Moximed, Neotract, New Enterprise Associates, Stanford University School of Medicine: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
M. James Barrett
Partner Emeritus of New Enterprise Associates
James Barrett is a General Partner at New Enterprise Associates (NEA). He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices, healthcare information systems, and healthcare services companies. He is a director of Cardioxyl Pharmaceuticals, GlycoMimetics, Inhibitex, Nucleonics, Peptimmune, Predictive Biosciences, Proteostasis Therapeutics, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and Zosano Pharma. Prior to joining NEA, James Barrett served as Founder, Chairman, and CEO of Sensors for Medicine and Science, where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, President and CEO of Life Technologies, and President and CEO of Bethesda Research Labs. Previously, he worked in various divisions of GlaxoSmithKline. James Barrett received a Ph.D. in Biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.
Follow M. James Barrett:
About GlycoMimetics, New Enterprise Associates, Senseonics: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Peter Barris
Managing General Partner of New Enterprise Associates
Peter joined New Enterprise Associates (NEA) in 1992 and has served as Managing General Partner since 1999. Since joining NEA, Peter has led investments in over 20 information technology companies that have completed public offerings or successful mergers. These include such industry pioneering companies as Amisys, CareerBuilder, InnerWorkings, Neutral Tandem, UUNET, and Vonage. Prior to joining NEA, Peter was President and Chief Operating Officer of Legent Corporation (LGNT) and Senior Vice President of the Systems Software Division of UCCEL Corporation (UCE). Both companies were ultimately acquired at valuations that were record breaking for their time. Earlier, Peter spent almost a decade at General Electric Company in a variety of management positions, including Vice President and General Manager at GE Information Services. Outside interests include serving on the Northwestern University Board of Trustees, the Dartmouth Tuck School Board of Overseers. Peter previously served on the Executive Committee of the Board of the National Venture Capital Association and was also a founding member of Venture Philanthropy Partners, a philanthropic organization in the Washington D.C. area. He has a BS degree in Electrical Engineering from Northwestern and an MBA from Dartmouth.
Follow Peter Barris:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Liza Landsman
General Partner of New Enterprise Associates
Prior to Jet, Liza was Chief Marketing Officer for E*TRADE and was responsible for their marketing initiatives, including customer engagement, analytics and insights, advertising, direct online and offline marketing programs, and branding campaigns. Prior to joining E*TRADE, Ms. Landsman held the position of Global Head of Digital at BlackRock, where she was responsible for firm-wide digital marketing strategy, including social media, web sites, and mobile applications. Before that, she was an Operating Partner at Bravas Partners. This followed a decade in senior management positions at Citigroup, where she focused primarily on driving engagement across customer channels, especially internet and mobile platforms. She also previously held several leadership roles at IBM in their e-commerce and personal systems group units, flooz.com, a start-up in the payments space and Writers House Inc. Ms. Landsman graduated magna cum laude from Cornell University. She joined the Board of Directors of Choice Hotels International (CHH) in 2014 where she is a member of both the Audit and Diversity Committees and has served on the Board of Directors of GO! Project, a New York City based non-profit organization that provides educational programs for children in need since 2012.
Follow Liza Landsman:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Scott Gottlieb
Partner of New Enterprise Associates
Follow Scott Gottlieb:
About American Enterprise Institute, CombiMatrix, National Academy of Medicine, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Robert Garland
Venture Partner of New Enterprise Associates
Dr. Garland joined NEA in 2003 and invests in biopharmaceuticals and medical devices. He is a director of 3-V Biosciences, Cardioxyl Pharmaceuticals, Trevena, Inc., and Zyngenia, Inc. Prior to NEA, in addition to clinical practice at the University of California, San Francisco (UCSF), he was with McKinsey & Company’s Pharmaceutical & Medical Products and Corporate Finance & Strategy practices. At McKinsey, Dr. Garland worked with biotech, pharmaceutical, medical device, diagnostics, and private equity clients to evaluate investments, formulate product and corporate strategies and build businesses. Dr. Garland completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF and received his MBA and MPH from the University of California, Berkeley, his MD from Baylor College of Medicine, and his BS in EE/Bioengineering from Rice University.
Follow Robert Garland:
About Cardioxyl Pharmaceuticals, NEAD, New Enterprise Associates, Trevena, Zyngenia: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Mike O’Dell
Venture Partner of New Enterprise Associates
Mike joined NEA in 2002 as a Venture Partner. His primary interest is the structure and behavioral dynamics of large, complex systems. He currently advises NEA portfolio companies Glacier Bay, Neutral Tandem, and Vonage. Mike came to NEA from UUNET Technologies where he was Chief Scientist, responsible for network and product architecture during the emergence of the Commercial Internet. Prior to UUNET, Mike held positions at Bellcore (now Telcordia), a GaAs SPARC supercomputer startup, and a US Government contractor. Mike served for four years as Area Director for Operations and Management in the IETF, authored several IDs and RFCs, and helped birth RADIUS and SNMPv3. Mike received his BS and MS in Computer Science from the University of Oklahoma.
Follow Mike O’Dell:
About Nealite, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Jeff Immelt
Venture Partner of New Enterprise Associates
Immelt has held several global leadership positions since coming to GE in 1982, including roles in GE’s Plastics, Appliances, and Healthcare businesses. In 1989 he became an officer of GE and joined the GE Capital Board in 1997. Immelt has been named one of the World’s Best CEOs three times by Barron’s, and since he began serving as chief executive officer, GE has been named America’s Most Admired Company in a poll conducted by Fortunemagazine and one of The World’s Most Respected Companies in polls by Barron’s and the Financial Times. Immelt was the chair of President Obama’s Council on Jobs and Competitiveness. He is a member of The American Academy of Arts & Sciences. Immelt earned a B.A. degree in applied mathematics from Dartmouth College in 1978 and an M.B.A. from Harvard University in 1982. He and his wife have one daughter.
Follow Jeff Immelt:
About GE Appliances, GE Healthcare, GE Plastics, New Enterprise Associates, Stanford Graduate School of Business: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Patrick Kerins
General Partner of New Enterprise Associates
Follow Patrick Kerins:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Colin H. Bryant
Operating Partner of New Enterprise Associates
Colin joined NEA in 2014 and is focused on working with NEA’s portfolio companies at the board level. Colin has two decades of experience in venture capital guiding successful strategic outcomes in technology-driven companies across a variety of sectors, including Metromile (NASDAQ: MILE), CareZone (acquired by Walmart), Bonsai.AI (acquired by Microsoft), OANDA (acquired by CVC Capital Partners), IfOnly (acquired by MasterCard), Graphite Systems (acquired by EMC), Fyusion (acquired by Cox), Curalate (acquired by BazaarVoice), Ketra (acquired by Lutron), 23andme and Aerospike. He currently serves on the boards of or is responsible for managing NEA’s investments in a wide range of companies, including Metromile, Splashtop, Sitetracker, Philo, Houzz, Logikcull, Fugue, Bridge International Academies, ThirdLove, Expel, Union, Fetchr, Hello Alfred, Gladly, Availink and Placester, among others. Prior to joining NEA, Colin spent 12 years at Paladin Capital Group, where he was responsible for investments in Royalty Pharma (NASDAQ: RPRX) and Cogent Communications (NASDAQ: CCOI). Prior to Paladin, Colin was a founding member of The Vigilant Investors Fund, a hedge fund in Santa Monica, California. Colin received his B.A. degree in Philosophy from Haverford College.
Follow Colin H. Bryant:
About Accubuilt, Adapx, CyberCore Technologies, HelioVolt, Luminus Devices, New Enterprise Associates, Previstar, Renewable Energy Group: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Peter Sonsini
General Partner of New Enterprise Associates
Pete joined NEA in 2005 and focuses on early-stage enterprise software, services, and systems companies. He is the co-head of NEA’s enterprise software practice group, and serves on several boards for NEA portfolio companies. Past investments include Pentaho (acquired by Hitachi), Teracent (acquired by Google) and Xensource (acquired by Citrix Systems). Prior to NEA, Pete was Senior Director of Strategic Alliances at VMware where he struck the company’s initial OEM deals and grew annual sales through OEMs from $0 to $40 million in four years. Pete ran product management at Mirapoint and worked in sales and marketing at Hewlett-Packard, including Worldwide Product Manager for the mid-range server business. Pete began his career at Montgomery Securities in the Technology Corporate Finance group.Pete received his MBA from the Kellogg School of Management at Northwestern University, and his BA in Political Economy from the University of California, Berkeley.
Follow Peter Sonsini:
About New Enterprise Associates, Stormpath: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Brooke Seawell
Venture Partner – Menlo Park of New Enterprise Associates
Brooke joined NEA in 2005 as a Venture Partner, focusing on software and semiconductor investments. Brooke currently serves on the board of directors of Glu Mobile (NASDAQ: GLUU), SiTime, SugarCRM, and Tableau Software. He also works closely with Tabula. He brings 25-plus years of experience in technology finance and operations. Brooke was most recently a Venture Partner with Technology Crossover Ventures (TCV). Prior to that, he was Executive Vice President of NetDynamics, an application server software company, which was acquired by Sun Microsystems in 1998. From 1991 to 1997, Brooke was Senior Vice President, Finance and Operations and CFO of Synopsys, an electronic design automation software company, which he took public in 1992. During his tenure at Synopsys, revenue grew from $20 million to $500 million. From 1983 to 1991 Brooke served as Vice President, Finance and Production and CFO of Weitek, a fabless semiconductor company, which he took public in 1988. Previously, he co-founded and was CFO of Southwall Technologies, a complex thin film coatings company. In 1990, Brooke was recognized by Upside magazine as one of the top 15 high-tech CFOs. He currently serves on the board of three public companies (NVIDIA, Informatica and Glu Mobile) and a variety of private companies. Brooke also serves on the Management Board of the Stanford Business School. He received his MBA and BA from Stanford University.
Follow Brooke Seawell:
About Formative Ventures, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Ed Mathers
General Partner of New Enterprise Associates
Ed Mathers joined NEA as a partner in August 2008 after a successful 26 years in the biopharm industry. Prior to joining NEA, Ed Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc, where he was responsible for leading the company’s venture capital subsidiary, and all business and corporate development activities. In addition, Ed Mathers was an integral member of the executive team that led to the sale of MedImmune to Astra Zeneca in 2007. Prior to joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in a variety of commercial roles, and started his career at Ortho Pharmaceuticals Corporation, an operating company of Johnson & Johnson. Ed Mathers currently sits on the Boards of Directors of Intarcia Therapeutics, Inc., Satori Therapeutics and Plexxikon Inc. He earned his bachelor’s degree in chemistry from North Carolina State University.
Follow Ed Mathers:
About GlaxoWellcome, Liquidia Technologies, MedImmune, NEAD, New Enterprise Associates, Ortho Pharmaceuticals Corporation: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Ron Bernal
Venture Partner of New Enterprise Associates
Ron is an entrepreneur and business executive who spent the first 24 years of his career in the high-technology operating world and the last 11 years as a venture capitalist. He joined NEA in 2010 as a Venture Partner and focuses on information and energy technology investments. He currently serves on the boards of Boulder Wind Power, Cohere Technologies, Gainspeed, Ketra, Kumu Networks, Leyden Energy and Solidfire and works closely with HelioVolt and Blue Jeans Network. Previous board memberships include Data Domain (acquired by EMC), Drobo (merged with Connected Data) HelioVolt, LifeSize (acquired by Logitech), Indicative (acquired by Nimsoft), Nicira (acquired by VMware), ProStor (acquired by Imation and Tandberg) and Redseal Systems. Prior to NEA, Ron was a Partner at Sequel Venture Partners and led the firm’s investments in HelioVolt and Buzzwire. Ron previously served as a Venture Partner at Sutter Hill Ventures, where he led the firm’s investments in Data Domain, Drobo, ProStor, LifeSize, Indicative and Redseal Systems. Prior to Sutter Hill Ventures, he was Chief of Staff/COO for the Service Provider and Product Technology Group Businesses at Cisco. He joined Cisco as part of the Growth Networks acquisition in 2000, where he was President and CEO. Ron co-founded Growth Networks, an internet switching fabric company, in 1998 while serving as an entrepreneur-in-residence at NEA. Prior to working with NEA, he spent more than seven years with Silicon Graphics, Inc. (SGI) in roles including Senior Vice president and General Manager of the $1 billion-plus server division and President of the MIPS group, the microprocessor subsidiary of SGI. Ron was also Vice President of Engineering and COO of Edge Computer, a computer company he co-founded in 1983. Ron also serves on the boards of Open Network Summit (ONS), Energy Fellows Institute, Colorado School of Mines Advisory, Colorado State University Ventures, and NREL VC advisory board. He holds a B.S. in electrical engineering from DeVry Institute of Technology.
Follow Ron Bernal:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Rick Yang
General Partner and Head of Consumer Technology Investing of New Enterprise Associates
Rick Yang joined NEA in 2007 and is focused on information technology and energy investments. He is currently on the board of Compass Labs, and was previously a director and is still active with One Block Off the Grid (acquired by Pure Energies Group). Rick also works closely with NEA’s investments in BloomReach, Boku, Boulder Wind Power, Braintree, Euclid, HelioVolt, SolFocus, Surf Air, SmartDrive, and Tabbedout. He was historically involved with Gaikai (acquired by Sony). Prior to joining NEA, Rick advised on and executed a number of strategic financing initiatives for leading public and private tech companies in the Credit Suisse Technology Group. Rick earned his bachelor’s degree in electrical engineering from Stanford University, where he was also a varsity swimmer.
Follow Rick Yang:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Tony Florence
General Partner of New Enterprise Associates
Tony is a General Partner and co-leads NEA’s Venture Growth Equity and Consumer Internet investment practices. Tony focuses on investments in the software and Internet sectors with emphasis on SaaS and marketplace ecommerce companies. In addition, he is actively involved in NEA’s investing activities in China. Tony has led investments in Care.com (NYSE: CRCM), Cvent (NYSE: CVT), Moda Operandi, Edmodo, EverFi, Casper, Raise.com, Jet.com, Goop.com and Wallapop. He led the firm’s investment in Quidsi (Diapers.com), which was acquired by Amazon in 2011. Prior to joining NEA, he was a Managing Director at Morgan Stanley and was Head of Technology Banking in New York, and was a member of the North American Management Committee for investment banking. Tony spent over a decade at Morgan Stanley focused on the software and Internet sectors, and also worked with a number of NEA’s companies in both IPOs and M&A transactions. Tony received an MBA and an A.B. in Economics from Dartmouth College.
Follow Tony Florence:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Mohamad Makhzoumi
General Partner of New Enterprise Associates
Mohamad first joined NEA as an associate in 2000 and now co-heads the healthcare services and healthcare information technology investment practice. Mohamad is currently a Director of American Pathology Partners, DaVita NephroLife, DSI Renal, Elements Behavioral Health, Nova Medical Centers, Radiology Partners, SCI Solutions and Simplex Healthcare. He is a Board Observer of BENU, Vantage Oncology and Welltok. Mohamad’s past investments include Bravo Health, CHG Healthcare, Long Term Care Group and ppoNEXT. Previously, Mohamad focused on growth equity investments at Summit Partners prior to which he worked with UBS Investment Bank where he concentrated on leveraged finance and sponsor-led transactions. Mohamad received a bachelor’s degree, with distinction, from the University of Pennsylvania and is an active participant in the cancer community having been a founding board member of Livestrong’s Young Leadership Cancer Council.
Follow Mohamad Makhzoumi:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Carol Gallagher
Venture Partner of New Enterprise Associates
Carol Gallagher joined NEA in October, 2014. She is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Dr. Gallagher raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead has continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
Follow Carol Gallagher:
About GlaxoSmithKline, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Jay Graf
Venture Partner of New Enterprise Associates
Jay Graf joined NEA in October 2005 as a Venture Partner focusing primarily on medical device investments. Jay comes to NEA after nearly 30 years experience in the healthcare industry. He currently serves on the boards of American Medical Systems, Anulex Technologies, CVRx, Denali Medical, Ivantis, Rotation Medical and VytronUS. Most recently, Jay was Group Chairman of Guidant where he directed Guidant’s four operating groups before retiring in 2004. From 1992-2000, Jay was President of Guidant’s Cardiac Rhythm Management Group, now owned by Boston Scientific. Prior to that, he was Executive Vice President and COO of CPI from 1990 to 1992. Jay held a variety of management positions with Eli Lilly’s Pharmaceutical and Medical Device Division between 1976 and 1990. He is a graduate of Boston University with a Bachelor of Science degree in Business and Economics, and earned a Masters in Business Administration degree in finance from Indiana University. Jay served in the United States Air Force where he achieved the rank of Captain.
Follow Jay Graf:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Melissa Taunton
Partner of New Enterprise Associates
Melissa joined NEA as a Partner in 2015. She focuses on talent acquisition at the executive level across the NEA portfolio. Melissa brings broad operating experience from the technology and healthcare sectors, along with a passion for cultivating relationships, to seek out best in class people who will build life-changing companies that have global reach. Melissa began her career in technology at Qualcomm (supply chain management), Hewlett Packard (global contract manufacturing strategy) and Netopia (strategic technology alliances). She then transitioned to healthcare, as President of Drip Drop, Inc. (an oral rehydration product for hospital and home use) and realized her passion for creatively improving human health and lives through access to technology solutions. She subsequently joined Khosla Ventures as an Operating Partner focused on finding the best people to advance cutting edge companies at the intersection of technology and life sciences. Melissa was born in Durban, South Africa and came to the United States as a young adult. She was captivated by the fascinating opportunities and technology developments that she saw in US companies and consequently made the Bay Area her home base. Melissa attended the University North Carolina at Chapel Hill and graduated from the University of San Diego with an MBA (Summa Cum Laude) in finance and marketing, specializing in international negotiations.
Follow Melissa Taunton:
About Broadway Angels, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Hilarie Koplow-McAdams
Venture Partner of New Enterprise Associates
Hilarie joined NEA in 2017 as a Venture Partner on the technology team, where she focuses on enterprise software and services. An enterprise software veteran, Hilarie spent the last three decades at growth-stage technology companies in operating and board roles. Most recently, Hilarie was President at New Relic, responsible for New Relic’s growth strategies, as well as leading global sales, marketing, customer success, support, and business development. Prior to New Relic, Hilarie was at Salesforce, where she was President and led the company’s worldwide sales teams and focused on growing the business globally. Hilarie joined Salesforce from Intuit, where she was Vice President of direct sales for small business and a member of the executive committee.
Follow Hilarie Koplow-McAdams:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Arno Penzias
Venture Partner of New Enterprise Associates
Arno Penzias joined New Enterprise Associates (“NEA”) in 1997 as a Venture Partner from Bell Labs, where he headed its research organization and served as its Chief Scientist.Arno is currently on the Board of HelioVolt and Terrajoule and serves as technical adviser, as needed, for a number of NEA companies, including: Bloom Energy, HelioVolt, Hillcrest Laboratories, Solar Junction, SolFocus, Spreadtrum Communications, Telegent Systems and Tri Alpha Energy. He has written two books and a number of articles on science and technology, especially their impact on business and society.A member of both the National Academy of Sciences and the National Academy of Engineering, he received a BS from City College of New York and a PhD from Columbia University.His awards include a number of honorary degrees, as well as other awards, for his contributions to science, R&D management and public service – most notably the 1978 Nobel Prize in Physics for his work in radio astronomy.
Follow Arno Penzias:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Elliott Sigal
Venture Partner of New Enterprise Associates
Elliott Sigal, M.D., Ph.D. joined NEA as a Venture Partner and Senior Advisor in 2014. He is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Dr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance.
Follow Elliott Sigal:
About Amgen, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Ann Bordetsky
Partner of New Enterprise Associates
Ann Bordetsky joined NEA as a Partner in 2021 and focuses on consumer and enterprise technologies with particular focus on the future of work, commerce and platforms. Ann has helped to build some of Silicon Valley’s most iconic technology companies in a variety of business, strategy and operating executive roles and has been a leading force in catalyzing diversity in tech as an operator, angel investor and advisor to January Ventures. Prior to NEA, Ann served as Chief Operating Officer of Rival Inc, a modern enterprise platform for live event commerce acquired by Live Nation/Ticketmaster in 2020, and an active operator angel investing in early stage saas, marketplace and consumer digital startups. She was previously Director of Business Development & Strategic initiatives at Uber, leading growth initiatives, strategic partnerships and new vertical formation. Prior to Uber, Ann was the Head of Commerce and Consumer Product Business Development at Twitter and held a variety of business development and GTM roles at pioneering early-stage marketplace and mobility startups (Wheelz and Better Place). Before joining the world of Tech and Silicon Valley startups, Ann served in government engagement and federal policy roles in DC at one of the nation’s top environmental think tanks. Ann holds an MBA from Stanford University and a bachelor’s degree in environmental science, policy and management from the University of California, Berkeley.
Follow Ann Bordetsky:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Matthew McAviney
Partner of New Enterprise Associates
Matt is a Senior Associate at F-Prime Capital and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2013, Matt was a healthcare consultant at Oliver Wyman, a biotech equity analyst at Robert W. Baird, and a healthcare investment banker at J.P. Morgan. He began his career researching lipid metabolism at the NIH. Matt holds a M.D. from the University of Illinois and a M.B.A. from the University of Chicago. He received his B.A. in biology with honors from the University of Chicago.
Follow Matthew McAviney:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
John Nehra
Retired Special Partner of New Enterprise Associates
John Nehra has been one of our directors since November 2000. From 1989 until his retirement in August 2014, John Nehra was affiliated with New Enterprise Associates (‘‘NEA’’), a venture capital firm, including, from 1993 until his retirement, as general partner of several of its affiliated venture capital limited partnerships. John Nehra also served as managing general partner of Catalyst Ventures, a venture capital firm, from 1989 to 2013. John Nehra served on the boards of a number of NEA’s portfolio companies until his retirement in August 2014 and remains a retired special partner of NEA. John Nehra is an experienced business leader with approximately 44 years of experience in investment banking, research and capital markets and he brings a deep understanding of our business and industry through his nearly 15 years of service as a member of the Board as well as significant experience in the healthcare industry through his involvement with NEA’s healthcare-related portfolio companies.
Follow John Nehra:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Blake Wu
Partner of New Enterprise Associates
Blake joined NEA in 2014 as an Associate on the Med Team. Prior to joining NEA, Blake was an Associate in the Private Equity Group at Ares Management, as well as an analyst in the Investment Banking Group at Moelis & Company in Los Angeles. At Moelis, Blake was a generalist, primarily focused on healthcare, business services and media. Blake’s previous work experience also includes Barclays Capital, where he was an Associate in the Equity Research Group, covering retail hardlines. Blake graduated from The Wharton School at the University of Pennsylvania, with a B.S in economics with concentrations in Finance, Real Estate and Management.
Follow Blake Wu:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Kavita Patel
Venture Partner of New Enterprise Associates
Follow Kavita Patel:
About New Enterprise Associates, The Brookings Institution, The World Economic Forum: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Michele Park
Partner of New Enterprise Associates
Follow Michele Park:
About New Enterprise Associates, The Blackstone Group Inc: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Albert Lee
Operating Partner – Design & Product of New Enterprise Associates
Albert Lee, a Managing Director in IDEO’s New York office, brings more than a decade of experience in digital product, communication, and venture design to IDEO. He specializes in developing new offerings and incubating ventures for clients based on consumer insights in a wide range of industries, including retail, financial services, consumer technology, and fashion.
Follow Albert Lee:
About All Tomorrows, New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Suzanne King
Partner of New Enterprise Associates
Follow Suzanne King:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Kate Barrett
Marketing Partner of New Enterprise Associates
Follow Kate Barrett:
About New Enterprise Associates: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Erin Stadler
Managing Partner of Boomtown Accelerators
Follow Erin Stadler:
About Boomtown Accelerators, Boomtown Accelerators, The Farm Atlanta: Boomtown’s bespoke accelerator programs help startups turn ideas into profitable, scalable businesses.
Mona Ashiya
Private Equity Partner of OrbiMed
Follow Mona Ashiya:
About OrbiMed: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Klaus Veitinger
Venture Partner of OrbiMed
Klaus Veitinger is currently a Venture Partner with OrbiMed and he served as Chairman of Promentis Pharmaceuticals from April 2008 until February 2014. During his prior 16-year pharmaceutical career, Klaus Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Klaus Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Klaus Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Klaus Veitinger received his medical degree and his doctorate (Ph.D.) from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.
Follow Klaus Veitinger:
About OrbiMed, PhRMA (Pharmaceutical Researcher and Manufacturers of America), Promentis Pharmaceuticals: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Carl L. Gordon
General Partner of OrbiMed
Carl Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Carl Gordon is active in both private equity and small-capitalization public equity investments.He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.He was a Fellow at The Rockefeller University from 1993 to 1995. Carl Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.
Follow Carl L. Gordon:
About OrbiMed: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Jonathan Silverstein
Co-Head of Private Equity and Managing Partner of OrbiMed
Jonathan Silverstein, JD, joined OrbiMed Advisors, LLC in 1998 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was a Director of Life Sciences in the Investment Banking Department at the Sumitomo Bank and an Associate at Hambro Resource Development. Mr. Silverstein has a JD and an MBA from the University of San Diego, and a BA in Economics from Denison University. Currently, Mr. Silverstein is the Chairman of Enobia Pharma, Inc., Cerapedics, Inc., and Gelesis, and he is a Director at superDimension, Ltd., Glaukos Corporation and Nxstage Medical, Inc. He has been a Director or observer in more than a dozen other companies, including: LifeCell Corporation, Given Imaging, Ltd., Cerexa, Inc. (sold to Forest Laboratories, Inc.), Peninsula Pharmaceuticals, Inc. (sold to Johnson & Johnson, Inc.), Predix Pharmaceuticals, Inc.(sold to Epix Pharmaceuticals, Inc.), Avanir Pharmaceuticals, Inc., Orthovita, Inc., Auxillium Pharmaceuticals, Inc., Bioenvision (sold to Genzyme Corporation), Adiana, Inc. (sold to Cytyc Corporation) and Adolor Corporation.
Follow Jonathan Silverstein:
About OrbiMed, The Silverstein Foundation: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Michael B. Sheffery
Partner & Co-Founder of OrbiMed
Michael B. Sheffery, Ph.D., is a founding Partner of OrbiMed. Dr. Sheffery was formerly Head of the Laboratory of Gene Structure and Expression at Memorial Sloan-Kettering Cancer Center. He received both his Ph.D. in Molecular Biology and his B.A. in Biology from Princeton University. Dr. Sheffery joined Mehta and Isaly in 1996 as a Senior Analyst covering the biotechnology industry.
Follow Michael B. Sheffery:
About OrbiMed: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Chau Khuong
Private Equity Partner of OrbiMed
Chau Q. Khuong joined OrbiMed Advisors in 2003 and is a Partner on the Private Equity team. Chau Khuong has experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer Associate in the New Ventures technology transfer group at Columbia University. At OrbiMed, Chau Khuong was actively involved investments in Arius Research, Inc. (acquired by Roche in 2008), Peninsula Pharmaceuticals, Inc. (acquired by Johnson & Johnson, Inc., in 2005), Cerexa, Inc. (acquired by Forest Laboratories, Inc., in 2007), Adiana, Inc. (acquired by Cytyc Corporation in 2007), Avanir (NASDAQ: AVNR), and Biodel, Inc. (NASDAQ: BIOD). He currently serves as Director or Observer on the Corporate Boards at Cerapedics, Glaukos Corporation, Intercept Pharma, Sonendo, and Pieris AG. Chau Khuong holds a BS in molecular biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.
Follow Chau Khuong:
About OrbiMed: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Kevin Koch
Venture Partner of OrbiMed
Kevin Koch is a Venture Partner with OrbiMed Advisors, LLC, and the President and CEO of Edgewise Therapeutics. He was formerly at Biogen as Senior Vice President of Drug Discovery: Chemical and Molecular Therapeutics, where he managed global drug discovery and the immunology and hematology teams. Previously, Kevin Koch served as the President, CSO, Board member and Co-Founder of Array BioPharma, where he oversaw the invention of over 20 clinical development candidates in multiple therapeutic areas. Prior to Array, Kevin Koch held senior positions at Amgen Inc. and Pfizer Central Research. He is the co-author or inventor of multiple patents and publications and received his PhD in Organic Chemistry from University of Rochester.
Follow Kevin Koch:
About Edgewise Therapeutics, OrbiMed: OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
David Tamburri
Managing Partner & CFO of Health Enterprise Partners
Follow David Tamburri:
About Columbia University in the City of New York, Health Enterprise Partners: Health Enterprise Partners is a private equity firm that provides its services for healthcare services and information technology companies.
Pete Tedesco
Vice President & Managing Partner of Health Enterprise Partners
Prior to joining HEP, Pete was a Vice President at Olympus Partners, a middle-market private equity firm managing over $5 billion. At Olympus, he was responsible for evaluating and executing leveraged buyout and growth equity transactions and served on the board of directors for companies across a variety of industries. Pete previously worked at Chicago-based private equity firm Waud Capital Partners, where he focused primarily on investments in the healthcare services sector, and in the Corporate Business Development group at Becton Dickinson & Co. (NYSE: BDX). Pete began his career in the Mergers & Acquisitions and Diversified Industrials groups at UBS Investment Bank. Pete holds an A.B. from Princeton University and an MBA from the Kellogg School of Management at Northwestern University.
Follow Pete Tedesco:
About Health Enterprise Partners: Health Enterprise Partners is a private equity firm that provides its services for healthcare services and information technology companies.
Frank Witney
Operating Partner of Ampersand Capital Partners
Frank Witney brings more than 30 years of leadership and innovation in the research, development, and commercialization of many life science products, including diagnostic and analytical instruments to Affymetrix. He previously served at Affymetrix as Executive Vice President and Chief Commercial Officer following the acquisition of Panomics Inc., a quantitative biology company which Witney had pioneered and served as president and chief executive officer for six years. Prior to returning to Affymetrix, Witney was President and Chief Executive Officer of Dionex Corporation, an ion and high performance liquid chromatography company which he led to an increase in market share across multiple markets and ultimately a successful acquisition by Thermo Fisher Scientific, Inc. Witney also served as President and Chief Operating Officer of Packard BioScience, where he oversaw global operations, research and development, manufacturing, and worldwide sales, achieving rapid growth in revenues and operating profits. When Packard was acquired by PerkinElmer Life Sciences, he became President of PerkinElmer’s Drug Discovery Tools division, managing the reagent and instrument business units for high-throughput screening, research products, genomics/proteomics, and liquid handling automation. Earlier in his management career, Witney held numerous positions at Bio-Rad Laboratories, including Group Operations Manager of the Life Science Group where he led successful efforts to enter rapidly growing markets for proteomics and bioassay technologies. Witney was a post-doctoral fellow at the National Institutes of Health and holds a doctorate in molecular and cell biology from Indiana University.
Follow Frank Witney:
About Ampersand Capital Partners: Ampersand is a middle market private equity firm focused on investments in two core sectors: Healthcare and Industrial.
David Warnock
CEO & Partner of Camden Partners
David is a Senior Partner of Camden Partners and co-founded the firm in 1995. He has over 25 years of investment experience and focuses on investments in the business and education sectors. He serves as Chairman of New Horizons Worldwide, Inc. and Calvert Education Services, LLC. In addition, he is a director of Primo Water Corporation, Questar Assessment, Inc., Ranir, LLC, Santa Rosa Consulting, Triumph Higher Education Group and Network for Good. He formerly served on the board of American Public Education, Inc., Nobel Learning Communities, Inc. Towne Park, Ltd., and National American University, all of which were Camden Partners portfolio companies. David was employed by T. Rowe Price Associates from 1983-1995. He served as President of T. Rowe Price Strategic Partners I & II as well as co-manager of the T. Rowe Price New Horizons Fund. David started his career at Welch and Forbes, Boston-based private trustees. David is also involved with numerous non-profit organizations. He is the Chairman of the Center For Urban Families and the Warnock Foundation, and was formerly the Chairman of the Greater Baltimore Committee. He is Founder and Trustee of the Green Street Academy in Baltimore City. He also serves as a trustee of the Baltimore Museum of Art and the Georgia O’Keeffe Museum. David earned a B.A. degree from the University of Delaware and a M.S. (in Finance) from the University of Wisconsin. David is also a Chartered Financial Analyst Charterholder.
Follow David Warnock:
About Camden Partners, Camden Partners, Center for Urban Families, Georgia O’keeffe Museum, Pinnacle Automotive Hospitality Services, Warnock Foundation: Camden Partners provides growth capital to companies in the education, healthcare and technology-enabled business services sectors.
Gary Swart
Partner of Polaris Partners
Gary Swart is a Venture Partner investing in technology companies from our San Francisco office. He was previously the CEO of oDesk, the world’s largest online workplace with more than one million clients and five million freelancers. Gary guided the company to industry leadership and through a merger with Elance, while serving as a leading voice for the future of work and emerging online work industry. Prior to oDesk, Gary was the VP of Worldwide Sales for Intellibank, responsible for building the direct and indirect sales organization and channel development. Previous to Intellibank, he was a Business Unit Executive for IBM’s Rational Software Product Group. Gary joined IBM through the acquisition of Rational Software where he ran Western Field Operations and held a number of other senior management positions including Americas Medium Business Leader, Area Manager, District Manager, and Director of Telesales. Prior to Rational Gary held a number of sales, management, and leadership positions with Pure Software, subsequently Pure-Atria, which previously merged with Rational. Gary serves as a thought leader on the future of work, how best to hire and manage teams, and on the rise of the “freelance economy.” He has spoken at the Inc. Leadership Conference, The Economist’s Ideas Economy Panel, SXSW, TechCrunch 50, GigaOM Net:Work, and at HBS – which teaches a case study on oDesk. His commentary has appeared in a variety of publications including LinkedIn, Forbes, TechCrunch, The Washington Post and The Next Web. And he’s appeared on TV and radio outlets, including CNBC, BBC, Bloomberg TV, National Public Radio, Startups Uncensored, NPR, and the Fox Business Network. Gary holds a Bachelor of Science degree in Business Administration from the University of Maryland.
Follow Gary Swart:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Amir Nashat
Managing Partner of Polaris Partners
Amir Nashat is a Managing Partner in Polaris’ Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare. Amir currently represents Polaris as a Member of the Board of Directors at AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences, and Syros Pharmaceuticals. Additionally, Amir has served as a Member of the Board of Directors at Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene) and Sun Catalytix (Lockheed Martin). At Living Proof and Sun Catalytix, Amir served as the company’s initial Chief Executive Officer. Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. Amir previously served on the Board of the New England Venture Capital Association. Amir has been named to the Forbes Midas List of “Top 100 Venture Capitalists.” Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. degree and B.S. degree in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Follow Amir Nashat:
About Polaris Partners, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
David Barrett
Managing Partner of Polaris Partners
20 yr operating exec & entrepreneur. Mentor, coach & partner to innovators, entrepreneurs & technology start-ups. 14 yr early & growth-stage investor focusing on SaaS, data/analytics, cloud infrastructure and healthcare technologies.
Follow David Barrett:
About Polaris Partners, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Terrance McGuire
Founding Partner of Polaris Partners
Mcguire has served as a member of Acceleron’s board of directors since 2005.McGuire co-founded Polaris Partners in 1996 and is currently one of their general partners.Prior to starting Polaris Partners,.McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical and information technology companies.He currently serves on the board of directors of Adimab/Arsanis, Aero Designs/Wiki Cells, Arsenal Medical/480 Biomedical, Iora Health, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, NextCode, Pulmatrix, SustainX, and Trevena. He has served on the board of directors of numerous other companies, including Remon Medical Technologies, GlycoFi, Akamai Technologies, Aspect Medical Systems, Cubist Pharmaceuticals, Transform Pharma, and deCODE genetics.McGuire is the former chairman of the National Venture Capital Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School. McGuire received a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.
Follow Terrance McGuire:
About Advanced Inhalation Research, Inspire Pharmaceuticals, MicroCHIPS, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Pat Kinsel
Partner of Polaris Partners
Pat Kinsel is a Venture Partner at Polaris Partners. He joined the firm in August 2013. Pat specializes in designing and building innovative technologies and consumer products. He has built products in the mobile, search, social, local, productivity, and collaboration spaces. Pat joined Polaris from Spindle, a company he co-founded and led as CEO from December 2010 until it was acquired by Twitter in June 2013. Spindle developed patent pending search technology to surface the most timely and interesting updates from services like Twitter and Facebook. Spindle’s technology advanced search by understanding the implicit context made available by mobile devices to compose a far richer query than a keyword alone ever could. Prior to Spindle, Pat spent several years at Microsoft leading teams within Microsoft FUSE Labs and Microsoft Startup Labs. Pat was responsible for incubating new concepts and bringing them to market. In this role, he led development of Docs.com. Launched by Mark Zuckerberg at F8 in 2010, Docs.com was a collaboration between Microsoft and Facebook to bring Microsoft Office Online to the Facebook audience. Before Docs.com, Pat built several social discovery applications and helped launch Bing’s social search efforts, ultimately bringing Bing Social Search to market in October 2009. At Microsoft, Pat was a co-inventor of several pending patents in the areas of social search and collaboration.
Follow Pat Kinsel:
About Harvard Innovation Labs, Notarize, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Isaac Ciechanover
Partner of Polaris Partners
Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in October 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene’s Executive Director in Business Development, he spearheaded the company’s venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company’s first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures’ healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. in Psychology from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an MBA from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd’s “The Dark Side of the Moon,” Radiohead’s “OK Computer” and Ruggero Leoncavallo’s Italian opera, Pagliacci, with Herbet Von Karajan conducting.
Follow Isaac Ciechanover:
About Polaris Partners, Santa Maria Biotherapeutics: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Robert Metcalfe
Partner Emeritus of Polaris Partners
Robert “Bob” Metcalfe is Professor of Innovation and Murchison Fellow of Free Enterprise in The University of Texas at Austin’s Cockrell School of Engineering. Dr. Metcalfe was an Internet pioneer at MIT starting in 1970 and in 1973 received his PhD from Harvard for Packet Communication. He invented Ethernet in 1973 and founded 3Com Corporation (now part of HP) in 1979. Bob was also CEO of IDG’s InfoWorld Publishing Company (1992-1995). For eight years, he wrote an Internet column read weekly by 629,000 information technologists. He also wrote for The American Spectator, Forbes, Technology Review, The New York Times, The Wall Street Journal, and Wired. For nearly a decade, Bob was a venture capitalist at Polaris Partners, where he invested in early-stage technology companies.
Follow Robert Metcalfe:
About Polaris Partners, SiOnyx, The University of Texas at Austin, The University of Texas at Austin, TriplePundit: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Brian Chee
Managing Partner of Polaris Partners
Follow Brian Chee:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Jon Flint
Founding Partner of Polaris Partners
Jon originated Living Proof’s vision of assembling a team of medical and biotech scientists to develop advanced technology for consumer hair and skin products.Jon served as CEO of Living Proof from November 2010 through December 2011.He is also the co-founder and a managing general partner of Polaris Venture Partners, a $3 billion venture capital fund with offices in Boston, New York City, and San Francisco.Jon’s current board seats include Athletes’ Performance and JibJab Media. Experience: Prior to founding Polaris, Jon was a partner with Burr, Egan, Deleage & Co., which he joined in 1984. Before joining BEDCO, he was an associate at the Boston law firm of Testa, Hurwitz and Thibeault, where he represented venture capital firms and high technology companies.Prior to Testa, Hurwitz and Thibeault, Jon gained substantial investigative experience during his service on the Impeachment Inquiry Staff of the U.S. Judiciary Committee and on the Watergate Special Prosecution Force. Boards and Education: Jon currently represents Polaris on the boards of Allurent, Athletes’ Performance, JibJab Media, Inc., Living Proof, Inc., and Modelinia, Inc.Jon’s prior investments include Allaire, American SuperConductor, Avici Systems, Centra, Conductus, Exchange.com, Mariner Health Care, Powersoft, and SolidWorks.Jon holds a JD from the University of Virginia Law School and a BA with high honors from Hobart College.
Follow Jon Flint:
About Icelandic Provisions, Polaris Founders Capital, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Steve Arnold
Co-Founder and Partner Emeritus of Polaris Partners
Prior to starting Polaris, Steve served as a special advisor to Burr, Egan, Deleage & Co. following more than 10 years in executive positions in the software industry. He served as vice president of Broadband Media Applications at Microsoft Corporation and as president and CEO of Continuum Productions (now Corbis), a private company founded by Bill Gates to pioneer the creation of large digital libraries for online distribution. Before coming to Continuum, Steve served as vice president and general manager of LucasArts Games and Learning divisions, and vice president of the New Media Group at Lucasfilm Ltd. He continues to serve as vice chairman of the board of directors of the George Lucas Educational Foundation. Steve holds a BS with honors from Macalester College and an MA and PhD from the California Institute of Integral Studies (CIIS) in San Francisco.
Follow Steve Arnold:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Darren Carroll
Partner of Polaris Partners
Mr. Darren Carroll leads the New Ventures Division of Eli Lilly and Company which includes both Lilly Ventures and Lilly Asian Ventures where he is the Senior Managing Director. Prior to assuming his current role, Mr. Carroll was the founding chief executive officer of InnoCentive, Inc., the first e-business venture created by Lilly. Among other positions Mr. Carroll has held at Lilly, he was the U.S. attorney for Prozac®.
Follow Darren Carroll:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Dan Lombard
Partner of Polaris Partners
Dan joined Polaris as a Principal in 2015. He focuses primarily on growth equity investments and buyout opportunities in software and technology-enabled services. Prior to joining Polaris, Dan was a Vice President with H.I.G. Growth Partners, a private equity firm focused on recapitalizations of growth-oriented, lower middle market businesses. While at H.I.G., Dan was responsible for sourcing, executing and monitoring investments in software, internet, and business services. He also served on the boards of several companies. Previously, Dan served as an associate at Symmetric Capital, where he sourced and executed investments in software, healthcare and business services. He also was an investment banking analyst at Bank of America in San Francisco, where he worked with growth-oriented technology and healthcare companies on private capital raises and recapitalizations. Dan received his MBA from the Tuck School of Business at Dartmouth, where he was recognized as an Edward Tuck Scholar, and a BA from Yale University.
Follow Dan Lombard:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Avak Kahvejian
General Partner of Flagship Pioneering
Avak Kahvejian joined Flagship Ventures in 2011 as a Partner in VentureLabsTM, bringing nearly 7 years of operational experience in the biomedical tools space. Prior to Flagship, Avak was at Helicos BioSciences, a Flagship VentureLabsTM company which developed and commercialized the world’s first single molecule sequencing technology. At Helicos since 2004, Avak held various business development, product management, marketing and sales roles. Most recently, as Vice President, Business Development for Helicos, he focused on establishing strategic partnerships in the areas of high-throughput sequencing and molecular diagnostics, leveraging the technology’s unique capabilities. Avak earned his PhD from McGill University in the laboratory of Dr. Nahum Sonenberg, where his research focused on modulators of mRNA translation and their regulation. During his studies at McGill, Avak was awarded a Canadian Institutes of Health Research operating grant as a co-investigator to Dr. Sonenberg, and was selected for the Dean’s Honour List upon graduation. At Flagship, Avak is developing new internally-generated ventures as part of VentureLabsTM and he is responsible for marketing and development firm-wide. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Avak Kahvejian:
About Flagship Pioneering, Laronde: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Geoffrey von Maltzahn
General Partner of Flagship Pioneering
Geoffrey von Maltzahn is Co-Founder, Chief Executive Officer, and Director of Tessera Therapeutics, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. He is also a co-founder of Sana Biotechnology, Indigo Agriculture, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), Generate Biomedicines, and others. Geoffrey currently serves as Chief Executive Officer and Director of Generate Biomedicines, Chief Innovation Officer and Director of Indigo, and Director of Kaleido Biosciences and Sana Biotechnology. He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, and as Kaleido’s Chief Executive Officer, where he led the company from inception to launching multiple clinical studies. Geoffrey also served as Chief Executive Officer of Indigo, where he led the development of the company’s technology platform and the discovery of the company’s first commercial products. Previously, Geoffrey was the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform. Geoffrey has been recognized with numerous patent grants, awards, and publications. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50’s Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Scientific American, Bloomberg Businessweek, Popular Science, MIT Technology Review, and other media. Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.
Follow Geoffrey von Maltzahn:
About Axcella, Flagship Pioneering, Indigo, Sienna Biopharmaceuticals, Tessera Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Lovisa Afzelius
Origination Partner of Flagship Pioneering
Follow Lovisa Afzelius:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Douglas Cole
Managing Partner of Flagship Pioneering
Follow Douglas Cole:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Harry Wilcox
General Partner of Flagship Pioneering
Follow Harry Wilcox:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Hari Pujar
Operating Partner of Flagship Pioneering
Follow Hari Pujar:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Stephen Berenson
Managing Partner of Flagship Pioneering
Follow Stephen Berenson:
About Flagship Pioneering, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Theodose Melas-Kyriazi
Executive Partner of Flagship Pioneering
Theodose Melas-Kyriazi has served as a member of our board of directors since February 2017.Melas-Kyriazi has also served as Chief Financial Officer of Levitronix Technologies LLC, a biotechnology company, since 2006. From 2003 to 2016, Melas-Kyriazi served as a director at Valeant Pharmaceuticals International, Inc. He spent nearly two decades at Thermo Electron Corporation (now Thermo Fisher Scientific) in a variety of roles, including six years as Chief Financial Officer. Melas-Kyriazi has been a director of a number of private and public biopharmaceutical companies. Melas-Kyriazi received his M.B.A. from Harvard Business School.
Follow Theodose Melas-Kyriazi:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Leda Trivinos
In-House Partner of Flagship Pioneering
Leda joined Flagship in 2015 as Partner, Intellectual Property. In this role, she helps formulate and manage the intellectual property strategy for VentureLabs innovations and provides counsel across the portfolio. Leda was most recently chief patent counsel for Momenta Pharmaceuticals Inc., a leader in the analysis and design of complex pharmaceutical products, where she led the company’s patent strategy to protect its technology and products, and to clear the way for successful product launches through patent enforcement and litigation. Prior to joining Momenta, she was Assistant General Counsel for intellectual property at Biogen Idec. She started her law career as an associate at Fish & Richardson PC, a global law firm specializing in intellectual property. Prior to earning her law degree from the University of California Berkeley School of Law, Leda was awarded a Ph.D. in cell and molecular biology from Northwestern University Medical School. Her research focused on motor proteins that drive intracellular transport. She also completed a post-doctoral research appointment at the lab of Suzanne R. Pfeffer Ph.D. at Stanford University’s Biochemistry Department, focusing on Rab proteins involved in membrane traffic in human cells. Leda was selected by SuperLawyers as a Massachusetts Rising Star in 2005 and 2006 and was recognized in 2015 in the first edition of Corporate IP Stars by Managing Intellectual Property magazine.
Follow Leda Trivinos:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
David Epstein
Executive Partner of Flagship Pioneering
Follow David Epstein:
About Axcella, Evelo Biosciences, Flagship Pioneering, Pelican Harbor Seabird Station, Rubius Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Stacie Rader
Partner, Chief People Officer of Flagship Pioneering
Prior to joining BG Medicine, Ms. Rader was Vice President at Flagship Ventures and Vice President, Human Resources, of NewcoGen since 1999. During her tenure with Flagship, she has consulted with numerous portfolio entities on HR operational issues. Ms. Rader has particular expertise in team building, staffing, and organizational development as well as compensation and benefits design and implementation. Prior to Flagship Ventures, she was Corporate Director of Worldwide Employment and Staffing for Applera Corporation (now Applied Biosystems) following the merger of Perkin Elmer and PerSeptive Biosystems in 1998. Ms. Rader was responsible for all human resources functions at PerSeptive from 1992 to 1998. During this period, she oversaw the hiring of 600 global employees and the implementation of core HR processes and programs as well as equity and compensation structures to accommodate the company’s rapid growth. She was also a key member of corporate due diligence teams for a number of PerSeptive acquisitions and was instrumental in the integration and assimilation process for the PE-PerSeptive merger and held an interim Vice President, Human Resources, role at Celera Genomics. Ms. Rader holds a B.S. from Babson College.
Follow Stacie Rader:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
TX Zhuo
General Partner of Fika Ventures
An entrepreneur at heart, TX has been involved with startups since his college days where he started then successfully sold an online college textbook marketplace. After a stint at McKinsey where he was a core member of their financial services and consumer goods practices, he came back to his roots and served as the CFO for an electric vehicle startup, Lit Motors. Thereafter, he worked for Innovation Endeavors, a seed stage venture fund backed by Eric Schmidt. In 2012, he co-founded Karlin Ventures, based in Los Angeles, where he served as the managing partner for 4 years before co-founding Fika Ventures. He is a strong proponent of transparency and efficiency and is constantly on the lookout for new platforms that seek to disrupt old, antiquated industries. Once a competitive badminton player who trained 4-5 days a week, he now can be found on the golf course or maxing out his ClassPass account on the weekends. He is also passionate about supporting initiatives that help cancer fighters. TX holds an MBA from Stanford and a BA in Mathematics and Economics from Wesleyan University.
Follow TX Zhuo:
About Fika Ventures: Fika Ventures is a seed fund that focuses on enterprise and B2B software, FinTech, marketplaces, and digital health.
Eva Ho
General Partner of Fika Ventures
Prior to Fika, Eva was a founding GP at Susa Ventures. She is a serial entrepreneur and founder, most recently a founding executive at Factual, a leading location data provider in Los Angeles. Prior, she was a Senior Product Marketing Manager at Google and Youtube for 5 years. Prior to Google, she was the head of marketing for Applied Semantics, a company that sold to Google in 2003. She also co-founded Navigating Cancer, a health startup, in 2008 which is now based in Seattle. She is active in the non-profit sector, serving on the boards of California Community Foundation, Ocean Conservancy, First Descents, and Iridescent. She is currently the Entrepreneur-in-Residence for the city of Los Angeles working with Mayor Eric Garcetti and his team. In her spare time, you can find her wandering remote geo coordinates, with a special affinity for cold, inhospitable places. Almost always, she is accompanied by her trusty camera and a backpack too large for her frame. Eva holds an MBA from Cornell and a BA from Harvard.
Follow Eva Ho:
About All Raise, Fika Ventures, MuckerLab: Fika Ventures is a seed fund that focuses on enterprise and B2B software, FinTech, marketplaces, and digital health.
Yair Cassuto
Partner of Pitango Venture Capital
Yair joined Pitango in April 2017. He is focused on early stage investments including deal sourcing, screening, due diligence and business development. Prior to Pitango, Yair worked at IBM in NY, focusing on Strategy and M&A. During his tenure at IBM, Yair was a Program Director at IBM Security, responsible on IBM’s strategic growth initiatives in cyber security. Previously, Yair was a member IBM’s Corporate Development team, where he worked on corporate wide strategic initiatives and M&A transactions. Before then, Yair worked as a consultant at McKinsey & Co. where he focused on growth and M&A strategy in tech, media and telecom. In addition, Yair served as a senior officer (Lt. Colonel equiv.) at the Israeli Prime Minister’s, responsible on R&D of advanced Hardware and Software. Yair holds a B.Sc. in Electronics Engineering with honors from University of Tel Aviv and an MBA from Wharton, University of Pennsylvania.
Follow Yair Cassuto:
About Pitango Venture Capital: Pitango Venture Capital specializes in early-stage, health-tech, and growth investments.
